ARROWHEAD PHARMACEUTICALS, INC. (ARWR): auditor change — Arrowhead Pharmaceuticals dismisses RSJ as auditor, engages KPMG

ARROWHEAD PHARMACEUTICALS, INC.

Dismissed Rose, Snyder & Jacobs (RSJ) as independent auditor effective December 1, 2023.
RSJ's audit reports for FY2022 and FY2023 were unqualified with no adverse opinion.
No disagreements or reportable events occurred in the two fiscal years or subsequent interim period.
Engaged KPMG as new independent auditor for fiscal year ending September 30, 2024.
Company did not consult KPMG on accounting principles, disagreements, or reportable events prior to engagement.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

ARROWHEAD PHARMACEUTICALS, INC. engaged KPMG, LLP as its auditor.

Action: engagement
Auditor: KPMG, LLP

Exact text from the filing

On December 01, 2023, the Audit Committee recommended, and the Board of Directors of the Company approved, the engagement of KPMG, LLP ("KPMG") as the Company's new independent registered public accounting firm for the Company's fiscal year ending September 30, 2024.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

ARROWHEAD PHARMACEUTICALS, INC. dismissed Rose, Snyder & Jacobs, LLP as its auditor.

Action: dismissal
Auditor: Rose, Snyder & Jacobs, LLP

Exact text from the filing

On December 01, 2023, the Audit Committee of the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the "Company") approved the dismissal of Rose, Snyder & Jacobs, LLP ("RSJ") as the Company's independent registered public accounting firm, effective immediately.

View on SEC.gov

Browse all auditor changes →

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-040776

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.